Editorial Note: This article is an internal production sample used exclusively for contributor outreach. All content, author bios, and associated data are strictly illustrative and fictional.
For most people with locally advanced rectal cancer, standard treatment is demanding. It typically combines chemotherapy, radiation, and surgery, and it can leave patients with lasting problems with bowel control, bladder function, sexual health, and fertility. Some need a permanent colostomy.
That is why results for a drug called dostarlimab have drawn so much attention from oncologists. For a specific subgroup of patients, it may offer a path that avoids surgery and radiation entirely. The FDA has now agreed to review it for this use on an expedited basis.
